TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20376479
Drug: Compression treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression treatment (n = 8) - wore full leg compression stockings for 12 h after exercise
Study: 15670888
Drug: dTpa formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTpa formulation with 0.3 mg aluminium
Study: 15670888
Drug: dTpa formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTpa formulation with 0.133 mg aluminium
Study: 15670888
Drug: dTpa formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTpa formulations with varying aluminium content
Study: 28148500
Drug: Calcium with
Normalized name: Calcium with Vit D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium with vitamin D (1000 mg elemental Ca with 400 IU vitamin D3/d)
Study: 9790450
Drug: Leukocyte interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leukocyte interferon-alpha (LE-IFN-alpha) administered at a dose of 3 MU three times a week for six months (group A)
Study: 9790450
Drug: Leukocyte interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leukocyte interferon-alpha (LE-IFN-alpha) administered at a dose of 3 MU three times a week for twelve months (group B)
Study: 15919695
Drug: Daily haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily haemodialysis (DHD)
Study: 8959286
Drug: Lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2 mg IV push)
Study: 25165161
Drug: Inactivated Influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Influenza Vaccine (IIV)
Study: 24633761
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during the first week of treatment.
Study: 2192634
Drug: Efamol (evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efamol (evening primrose oil) at a dose of 6 capsules daily
Study: 2192634
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent dose of capsules)
Study: 27709248
Drug: Two-injection digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-injection digital nerve block technique
Study: 27709248
Drug: Single-injection digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection digital nerve block technique
Study: 26670307
Drug: Colestilan (6-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestilan (6-15 g/day)
Study: 7898095
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists
Study: 11055468
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with beta-blockers and diuretics
Study: 8735863
Drug: Bronchodilators only
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators only
Study: 8153921
Drug: Bronchodilator tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator tests
Study: 8153921
Drug: Bronchodilator response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bronchodilator response at the start of the study
Study: 2873740
Drug: Beta blockers
Normalized name: BETA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blockers or clofibrate
Study: 2873740
Drug: Probucol or
Normalized name: probucol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol or diuretics
Study: 25864104
Drug: Ombrabulin plus
Normalized name: Ombrabulin
DrugBank: Ombrabulin (DB12882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin plus cisplatin (25 mg/m2 plus 75 mg/m2 every 3 weeks)
Study: 25864104
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus cisplatin (placebo plus 75 mg/m2 every 3 weeks)
Study: 22658401
Drug: Almorexant (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almorexant (200 mg p.o.) with ethanol (0.6 g/L i.v. ethanol clamp for 5 h)
Study: 22658401
Drug: Ethanol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.6 g/L i.v. ethanol clamp for 5 h)
Study: 19143675
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (K‐Y Jelly; Personal Products Inc., Raritan, NJ, USA)
Study: 16397514
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil monotherapy
Study: 16397514
Drug: Olmesartan medoxomil/HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil/HCTZ double therapy
Study: 16397514
Drug: Olmesartan medoxomil/HCTZ/Amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil/HCTZ/Amlodipine besylate triple therapy
Study: 15106393
Drug: Nine-week group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine-week group cognitive-behavioral therapy (CBT) intervention
Study: 11358906
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (leucocytic interferon alfa, escalating schedule for 12 months)
Study: 8181261
Drug: Nicotinamide (NCT)
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide (NCT) 25 mg kg‐1 day‐1
Study: 8181261
Drug: Nicotinamide (NCT)
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide (NCT) 25 mg kg‐1 day‐1 + Cyclosporin (CyA) 5 mg kg‐1 day‐1
Study: 12365468
Drug: Insulin only
Normalized name: Isophane insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin only (Control)
Study: 3063587
Drug: Magnesium aspartate
Normalized name: Magnesium aspartate
DrugBank: Magnesium aspartate hydrochloride (DB16619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium aspartate (Mg 5‐Longoral) at a daily dose of 15 mmol
Study: 16771960
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg t.i.d. started at admission (group A)
Study: 16771960
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group B) - antibiotics started after demonstration of necrosis
Study: 15273638
Drug: One-visit endodontic
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-visit endodontic treatment (including a 10‐min intraappointment dressing with 5% iodine‐potassium‐iodide)
Study: 11453892
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg twice daily for 7 days)
Study: 7912102
Drug: Pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5 mg twice daily for 7 days)
Study: 7912102
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg twice daily for 7 days)
Study: 3579530
Drug: Integrated behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated behavioral therapy
Study: 3579530
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy (Bobath therapeutic exercises)
Study: 9443427
Drug: Intravenous conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous conjugated estrogens (1.25 mg)
Study: 10336572
Drug: Diltiazem 200
Normalized name: diltiazem hydrochloride 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 200 mg
Study: 7690093
Drug: Diltiazem 300
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 300 mg
Study: 11600740
Drug: Rheumatoid Arthritis
Normalized name: Rheumatoid arthritis nuclear antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire applied to patients with increasing difficulty in performing activities of daily living
Study: 31443789
Drug: Voretigene neparvovec-rzyl
Normalized name: Voretigene Neparvovec-rzyl
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voretigene neparvovec-rzyl (VN) gene therapy, 1.5×10^11 vector genomes (vg) per eye, subretinal injection.
Study: 30261008
Drug: Metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2 × 850 mg) for 7 days
Study: 14513291
Drug: [123I]IPT administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: [123I]IPT administration
Study: 6896646
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of allopurinol (1H‐pyrazolo‐(3,4‐d) pyrimidin‐4‐ol) administered orally for 7 days
Study: 20002779
Drug: 0.7 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/day rhGH for 40 weeks
Study: 16223204
Drug: DHEP lecithin
Normalized name: Lecithin
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP lecithin gel (1.3%) applied 5 g t.i.d. for 10 days
Study: 16223204
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied 5 g t.i.d. for 10 days
Study: 10447627
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (600 cGy single dose between 2nd and 4th postoperative day)
Study: 10447627
Drug: Indomethacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (2 x 50 mg per day from 1st to 42nd postoperative day)
Study: 2233916
Drug: Methylprednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (40 mg) every 6 hours for 7 days
Study: 20179669
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment alone
Study: 535845
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (diet + d-triiodothyronine)
Study: 27093128
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment (MBT) adherence and competence
Study: 12411657
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (background risk)
Study: 25630353
Drug: Continued seizures,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued seizures, adverse events, and failure of initial treatment
Study: 25630353
Drug: Treatment withdrawal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment withdrawal
Study: 23520669
Drug: Chemoradiation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation plus topical application of honey
Study: 12563568
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg)
Study: 10546920
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg)
Study: 27824680
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg)
Study: 9204594
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg for 28 days, amoxicillin 3 x 500 mg for 7 days, metronidazole 3 x 500 mg for 5 days
Study: 9204594
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg for 28 days, ACA (amoxicillin 500 mg plus clavulanic acid 125 mg) 3 x 625 mg for 7 days, metronidazole 3 x 500 mg for 5 days
Study: 8128836
Drug: Physostigmine (intravenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (intravenous, 2 hours)
Study: 8128836
Drug: Tetrahydroaminoacridine (THA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrahydroaminoacridine (THA, mean dose 104 ± 20 mg/day, 6 weeks)
Study: 1941390
Drug: Ibuprofen (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (both dosages)
Study: 29045584
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT)
Study: 16239807
Drug: Shock wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock wave therapy
Study: 27814307
Drug: Placebo shock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo shock wave therapy
Study: 21928913
Drug: Zolpidem extended-release
Normalized name: zolpidem Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem extended-release (12.5 mg)
Study: 15117561
Drug: Honey solution
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey solution (administered for 15 days)
Study: 8607570
Drug: Honey (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey (30 g)
Study: 15117561
Drug: Sucrose (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (30 g)
Study: 11961050
Drug: Intravenous ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ALA (100 mg)
Study: 11961050
Drug: Oral ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ALA (100 mg)
Study: 8158698
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy and surgery
Study: 7891249
Drug: Subgingival chlorexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival chlorexidine gel
Study: 21358290
Drug: Ketorolac 0
Normalized name: KETOROLAC 0.3/P-EPHR 1% CONC OPH IRR 4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0 mg
Study: 8600742
Drug: Nonaugmented and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonaugmented and ligament augmentation device‐augmented repairs
Study: 1234497
Drug: ICI 66,082
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 66,082 (200 mg)
Study: 1234497
Drug: Water (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (control treatment)
Study: 22708881
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list condition (start cognitive behaviour therapy after 6 months)
Study: 21163776
Drug: e-therapy program
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-therapy program (n = 78)
Study: 18372693
Drug: Nutrition (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition (daily protein supplement)
Study: 9526817
Drug: Atorvastatin 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 5, 20, and 80 mg/day
Study: 18184901
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg
Study: 29417786
Drug: Knowledge assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge assessment regarding vaccine preventable diseases
Study: 26238111
Drug: Real acupuncture
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real acupuncture treatment (manual acupuncture plus electroacupuncture)
Study: 23026870
Drug: Real acupuncture
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real acupuncture treatment
Study: 23377586
Drug: Dorzolamide/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol fixed combination (DTFC)
Study: 18293187
Drug: Latanoprost/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost/timolol fixed combination (LTFC)
Study: 16939542
Drug: Fluvastatin 20-80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20-80 mg/day
Study: 11095257
Drug: PTMR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTMR with a holmium:YAG laser plus continued medical treatment
Study: 11095257
Drug: Continued medical
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued medical treatment only
Study: 25495390
Drug: Treated low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated low thyroid hormone group
Study: 25495390
Drug: Untreated low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated low thyroid hormone group
Study: 31659847
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection (ESI)
Study: 20194711
Drug: Amylin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amylin infusion
Study: 20194711
Drug: GLP-1 and
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 and amylin infusions
Study: 7762497
Drug: Long-acting diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting diltiazem 300 mg/day and aspirin 160 mg/day
Study: 492836
Drug: Amoxicillin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (25 mg/kg)
Study: 23844756
Drug: Oral combination
Normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combination of diosmin (300 mg/day), C. asiatica (15 mg/day) and Melilotus (160 mg/day)
Study: 22013932
Drug: Nadroparin (excessive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (excessive dosage)
Study: 22013932
Drug: Nadroparin (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (reduced dosage)
Study: 19211706
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU) 160 mg/day
Study: 19211706
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (TU) 80 mg/day
Study: 3556202
Drug: High-dose budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose budesonide (1600 micrograms/day)
Study: 9122535
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg
Study: 8841162
Drug: Medical nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical nutrition therapy from a registered dietitian (one or three visits) in addition to physician or nurse counseling and Grocery Shopping Guide.
Study: 6662159
Drug: Clonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3 mg p.o.) plus maprotiline (100 mg in 4 divided doses over 22 h)
Study: 6662159
Drug: Maprotiline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (100 mg in 4 divided doses over 22 h)
Study: 30845034
Drug: Sacroiliac joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacroiliac joint arthrodesis with triangular titanium implants
Study: 26318445
Drug: Ginger (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (2 g/day of ginger powder for 12 weeks)
Study: 26318445
Drug: Placebo (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corn starch as two 1 g tablets for 12 weeks)
Study: 25257359
Drug: Single-dose 300,000-IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 300,000-IU intramuscular injection of vitamin D3
Study: 9680495
Drug: Albuterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (200 micrograms administered via a Volumatic spacer)
Study: 9680495
Drug: Prophylactic anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anti-inflammatory treatment
Study: 2643863
Drug: Hydrochlorothiazide (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (in combination)
Study: 29930261
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) injections
Study: 29930261
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) injections
Study: 29930261
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injections
Study: 29203734
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg once daily for 6 months)
Study: 24016492
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus early rhythm control therapy (antiarrhythmic drugs, catheter ablation, and patient-operated ECG device)
Study: 24016492
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (anticoagulation, therapy of underlying heart disease, and rate control)
Study: 2409990
Drug: Intravenous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ethanol (10% v/v; 300 mg kg‐1 body weight for 30 min followed by 3 mg kg‐1 min‐1 for 2 hr)
Study: 2409990
Drug: Intravenous NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous NaCl (0.15 M)
Study: 30565779
Drug: Statin initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin initiation in women with total cholesterol > 240 mg/dL vs < 200 mg/dL during ATP-II period
Study: 11974895
Drug: Medium-flow inhalation
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-flow inhalation of fluticasone dipropionate (DFP) (70 L/min)
Study: 7772974
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (nebulized 4% lidocaine, 20 ml via oropharynx + transtracheal injection of 4% lidocaine, 3 ml)
Study: 7772974
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block (bilateral glossopharyngeal and superior laryngeal nerve blocks with 2% lidocaine, 0.5‐2 ml per injection site + transtracheal injection of 4% lidocaine, 3 ml)
Study: 2182430
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in second or later remission
Study: 219267
Drug: Thymosin fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin fraction V, 20 mg/sq m, twice weekly during the initial six weeks of chemotherapy
Study: 219267
Drug: No thymosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thymosin treatment during the initial six weeks of chemotherapy
Study: 30339627
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) at a dosage of 1000 mg/m every 2 weeks for 6 months
Study: 30339627
Drug: S-1 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 at a dosage of 80 mg/m/d for 28 days every 6 weeks for 6 months
Study: 23202265
Drug: Conditional cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditional cancer treatment subsidy
Study: 22510537
Drug: Classification-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classification-based physical therapy